The global Gastric Electrical Stimulation Systems Market continues to demonstrate steady growth as healthcare providers increasingly adopt advanced neuromodulation technologies for the treatment of gastroparesis and obesity. According to the latest industry analysis, the market was valued at US$ 145.0 Mn in 2021 and is projected to surpass US$ 273.7 Mn by 2031, expanding at a compound annual growth rate (CAGR) of 6.5% during the forecast period from 2022 to 2031. Rising prevalence of gastrointestinal disorders, increasing obesity rates, and continuous technological innovation are creating favorable conditions for sustained market expansion worldwide.

👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85272

Market Overview

Gastric electrical stimulation (GES), also known as gastric pacing or implantable gastric stimulation, has emerged as an effective therapeutic option for patients suffering from medically refractory gastroparesis while also showing significant potential in obesity management. The technology utilizes implantable neurostimulators that deliver controlled electrical pulses to the stomach muscles, improving gastric motility and reducing symptoms such as chronic nausea and vomiting. Continuous research has enabled manufacturers to improve device efficiency, patient comfort, and treatment outcomes. Furthermore, healthcare providers are increasingly recognizing GES as a reliable alternative for patients who do not respond adequately to conventional drug therapies.

Market Size and Growth

The market generated US$ 145.0 Mn in revenue during 2021 and is forecast to exceed US$ 273.7 Mn by 2031, reflecting a stable 6.5% CAGR throughout the assessment period. Market growth is primarily fueled by increasing diagnosis rates of gastroparesis, growing diabetic populations, favorable reimbursement policies, and rising healthcare expenditure across developed and emerging economies. Technological innovations such as miniaturized gastric stimulators with wireless charging capabilities and minimally invasive implantation techniques are expected to create significant commercial opportunities over the coming years. These advancements are expected to reduce surgical complexity while improving patient compliance and long-term therapeutic outcomes.

Market Segmentation

Based on product type, high-frequency gastric electrical stimulators accounted for the largest market share in 2021 owing to their superior battery life, patient-friendly implantation procedures, and increasing clinical adoption. By application, the gastroparesis segment dominated the global market due to widespread clinical acceptance of gastric electrical stimulation as an alternative treatment for medication-resistant cases. In terms of end users, hospitals and clinics represented the leading segment as they continue to perform the majority of gastric neurostimulator implantation procedures supported by advanced surgical infrastructure and experienced healthcare professionals.

Regional Analysis

North America maintained its dominant position in the global market during 2021 due to advanced healthcare infrastructure, favorable reimbursement frameworks, increasing awareness among healthcare professionals, and supportive clinical guidelines for gastric electrical stimulation therapies. Strong regulatory support and continuous product innovation further contribute to regional leadership.

Meanwhile, Asia Pacific is expected to register the fastest growth throughout the forecast period. Rapid improvements in healthcare infrastructure, expanding elderly populations, increasing prevalence of obesity and diabetes, and growing awareness regarding advanced gastrointestinal treatments are accelerating market demand across countries including China, India, and Japan.

Competitive Landscape

The competitive environment remains moderately consolidated, with companies focusing on technological innovation, strategic partnerships, mergers, acquisitions, and product launches to strengthen their market positions. Leading participants include Medtronic plc, ReShape Lifesciences, Inc., Intrapace, Inc. (InCube Labs), and Changzhou Rishena Medical Device Co., Ltd.

Recent product innovations include Medtronic's launch of the Enterra II 37800 Gastric Neurostimulator, while ReShape Lifesciences continues advancing neuromodulation technologies through positive preclinical developments for diabetes treatment.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453